Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cipargamin - Novartis

Next Previous
X
Search
Drug Profile

Cipargamin - Novartis

Alternative Names: Cipargamin; KAE-609; KAW-609; NITD-609

Latest Information Update: 15 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Medicines for Malaria Venture; Novartis; The Wellcome Trust
  • Class Antimalarials; Carbolines; Indoles; Pyridones; Small molecules; Spiro compounds
  • Mechanism of Action PfATP4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malaria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Falciparum malaria; Malaria

Most Recent Events

  • 02 Mar 2024 Novartis Pharmaceuticals completes a phase I trial in Malaria (In volunteers, Combination therapy) in United Kingdom (PO) (ISRCTN17232240)
  • 23 Jan 2024 Phase-II clinical trials in Falciparum malaria (Combination therapy, In children, In adults, In adolescents, In the elderly) in Ivory Coast, Ghana, Kenya (PO) (NCT05750628)
  • 23 Jan 2024 Phase-II clinical trials in Falciparum malaria (In adolescents, In children, In adults, In the elderly, Monotherapy) in Kenya, Ghana, Ivory Coast (PO) (NCT05750628)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top